BACKGROUND: The objective of the current study was to illustrate the influence of neoadjuvant therapy on the local immune response in patients with cervical carcinoma. METHODS: Uninvolved tumor-draining lymph nodes (TDLN) (n=158 lymph nodes), including internal, external, and common iliac lymph nodes as well as obturator, presacral, and aortic lymph nodes from 15 nontreated (NT) patients, 4 chemotherapy (CT)-treated patients, and 19 chemoradiation (CR)-treated patients, were analyzed for lymphocyte subset distribution and for the proliferative response of T cells to polyclonal activation and interferon-gamma (IFN-gamma) production. Lymphocyte subsets in peripheral blood also were assessed. RESULTS: TDLNs from CR-treated patients contained higher proportions of CD8+ cells and natural killer cells than NT and CT-treated patients (P values ranged from <0.05 to <0.01). TDLNs from CR-treated patients were enriched in activated-type CD4+ cells (HLA-DR+, CD134+, CD62L-, and CD25+ at an intermediate expression level; P values ranged from <0.05 to <0.01) and activated-type CD8+ cells (CD62L-, P<0.001) compared with NT patients. Concomitantly, there was a reduction in the proportion of naïve-type CD4+ and CD8+ cells (CD45RA+/CD62L+) (P<0.01 and <0.05, respectively). CR treatment increased the proportion of both CD4+ and CD8+ cells prone to produce IFN-gamma. All TDLNs contained suppressive CD4+ T regulatory (Treg) cells (CD25+ and CD152+ at a high expression level) whose frequency and suppressive activity was not influenced by the treatment. Therapy-induced changes in TDLN were mirrored only in part by respective alterations in peripheral blood. CONCLUSIONS: To our knowledge, the current study is the first to show that neoadjuvant therapy produces an enhancing effect on the immune competency of TDLNs from patients with cervical carcinoma. Copyright 2004 American Cancer Society.
BACKGROUND: The objective of the current study was to illustrate the influence of neoadjuvant therapy on the local immune response in patients with cervical carcinoma. METHODS: Uninvolved tumor-draining lymph nodes (TDLN) (n=158 lymph nodes), including internal, external, and common iliac lymph nodes as well as obturator, presacral, and aortic lymph nodes from 15 nontreated (NT) patients, 4 chemotherapy (CT)-treated patients, and 19 chemoradiation (CR)-treated patients, were analyzed for lymphocyte subset distribution and for the proliferative response of T cells to polyclonal activation and interferon-gamma (IFN-gamma) production. Lymphocyte subsets in peripheral blood also were assessed. RESULTS: TDLNs from CR-treated patients contained higher proportions of CD8+ cells and natural killer cells than NT and CT-treated patients (P values ranged from <0.05 to <0.01). TDLNs from CR-treated patients were enriched in activated-type CD4+ cells (HLA-DR+, CD134+, CD62L-, and CD25+ at an intermediate expression level; P values ranged from <0.05 to <0.01) and activated-type CD8+ cells (CD62L-, P<0.001) compared with NT patients. Concomitantly, there was a reduction in the proportion of naïve-type CD4+ and CD8+ cells (CD45RA+/CD62L+) (P<0.01 and <0.05, respectively). CR treatment increased the proportion of both CD4+ and CD8+ cells prone to produce IFN-gamma. All TDLNs contained suppressive CD4+ T regulatory (Treg) cells (CD25+ and CD152+ at a high expression level) whose frequency and suppressive activity was not influenced by the treatment. Therapy-induced changes in TDLN were mirrored only in part by respective alterations in peripheral blood. CONCLUSIONS: To our knowledge, the current study is the first to show that neoadjuvant therapy produces an enhancing effect on the immune competency of TDLNs from patients with cervical carcinoma. Copyright 2004 American Cancer Society.
Authors: Samuel D Bernal; Enrique T Ona; Aileen Riego-Javier; Romulo DE Villa; Gloria R Cristal-Luna; Josephine B Laguatan; Eunice R Batac; Oscar Q Canlas Journal: Oncol Lett Date: 2011-09-20 Impact factor: 2.967
Authors: Falguni Parikh; Dorothée Duluc; Naoko Imai; Amelia Clark; Krzys Misiukiewicz; Marcello Bonomi; Vishal Gupta; Alexis Patsias; Michael Parides; Elizabeth G Demicco; David Y Zhang; Seunghee Kim-Schulze; Johnny Kao; Sacha Gnjatic; Sangkon Oh; Marshall R Posner; Andrew G Sikora Journal: Cancer Res Date: 2014-10-15 Impact factor: 12.701
Authors: Alessandra Battaglia; Alexia Buzzonetti; Giovanni Monego; Laura Peri; Gabriella Ferrandina; Francesco Fanfani; Giovanni Scambia; Andrea Fattorossi Journal: Immunology Date: 2007-11-20 Impact factor: 7.397
Authors: Yasmin Hasan; Larissa Furtado; Ana Tergas; Nita Lee; Rebecca Brooks; Anne McCall; Daniel Golden; Shruti Jolly; Gini Fleming; Matthew Morrow; Kimberly Kraynyak; Albert Sylvester; Fauzia Arif; Matt Levin; David Schwartz; Jean Boyer; Jeffrey Skolnik; Mark Esser; Rakesh Kumar; Mark Bagarazzi; Ralph Weichselbaum; Michael Spiotto Journal: Int J Radiat Oncol Biol Phys Date: 2020-03-07 Impact factor: 7.038
Authors: J Visser; H W Nijman; B-N Hoogenboom; P Jager; D van Baarle; E Schuuring; W Abdulahad; F Miedema; A G van der Zee; T Daemen Journal: Clin Exp Immunol Date: 2007-11 Impact factor: 4.330